Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Equivalents (2016 - 2025)

AC Immune (ACIU) has disclosed Cash & Equivalents for 10 consecutive years, with $33.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 19.02% to $33.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.5 million through Dec 2025, down 19.02% year-over-year, with the annual reading at $33.5 million for FY2025, 19.02% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $33.5 million at AC Immune, down from $41.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $89.2 million in Q4 2021, with the low at $32.8 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $57.1 million, with a median of $41.4 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents crashed 63.23% in 2022, then soared 169.9% in 2023.
  • Over 5 years, Cash & Equivalents stood at $89.2 million in 2021, then crashed by 63.23% to $32.8 million in 2022, then surged by 169.9% to $88.5 million in 2023, then plummeted by 53.21% to $41.4 million in 2024, then fell by 19.02% to $33.5 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $33.5 million, $41.4 million, and $88.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.